Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Paradichlorobenzene→

Paradichlorobenzene Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
106-46-7
Molecular formula
C6H4Cl2
Molecular weight
147 g/mol
Drug class
Volatile aromatic chlorinated hydrocarboncerumenolytic component in ear-wax removal preparations
Mechanism of action
A volatile chlorinated aromatic compound used as one component of multicomponent cerumenolytic ear drops. The combined oil, solvent and softening formulation helps soften and facilitate removal of impacted cerumen; the clinical effect should be attributed to the full product rather than paradichlorobenzene alone.
Indications / reported uses
  • Used as a component of combination ear drops intended to soften and assist removal of impacted earwax. It is not a stand-alone therapeutic agent or a treatment for ear infection.

Sources: https://www.paladin-pharma.com/our_products/Cerumol_Insert_En.pdf · https://www.centaurpharma.com/downloads/2025/entchestphysician/others/Waxodiz%20Ear%20Drops%20PI.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Paradichlorobenzene Environmental Risk Assessment (ERA) (the Paradichlorobenzene ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.